December 11, 2017 / 4:44 PM / 2 years ago

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

Dec 11 (Reuters) - Almirall SA:

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

* ALMIRALL SA - CO AND ATHENEX HAVE ENTERED INTO A PARTNERSHIP TO DEVELOP AND COMMERCIALIZE KX2-391 IN UNITED STATES AND EUROPE

* ALMIRALL - ATHENEX WILL GRANT EXCLUSIVE LICENSE TO ALMIRALL TO RESEARCH, COMMERCIALIZE KX2-391 IN THE U.S., EUROPEAN COUNTRIES, INCLUDING RUSSIA

* ALMIRALL SA - UNDER TERMS OF PARTNERSHIP AGREEMENT, ATHENEX WILL RECEIVE AN UP-FRONT FEE AND NEAR-TERM PAYMENTS OF UP TO $55 MILLION

* ALMIRALL SA - ATHENEX WILL BE ELIGIBLE TO RECEIVE LAUNCH AND ADDITIONAL INDICATIONS MILESTONES FOR $65 MILLION

* ALMIRALL SA - DEAL INCLUDES SALES PERFORMANCE MILESTONES OF KX2-391 ESTIMATED TO BE $155 MILLION

* ALMIRALL - THERE WILL BE TIERED ROYALTIES STARTING AT 15% BASED ON ANNUAL NET SALES, WITH INCREMENTAL INCREASES IN ROYALTY RATES WITH INCREASED SALES

* ALMIRALL SA - ATHENEX WILL BE RESPONSIBLE FOR CONDUCTING ALL PRECLINICAL AND CLINICAL STUDIES UP TO U.S. FDA APPROVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below